Trial Profile
Candesartan use in hypertrophic and non-obstructive cardiomyopathy estate (The CHANCE): a double-blind, placebo-controlled, randomized, multicenter study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Sep 2007
Price :
$35
*
At a glance
- Drugs Candesartan cilexetil (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Therapeutic Use
- Acronyms CHANCE
- 01 Sep 2007 Results have been reported.
- 27 Feb 2007 New trial record.